Drug Profile

FabG1 2139

Alternative Names: Fab-G1-2139

Latest Information Update: 24 Feb 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator FatiAbgen
Developer FatiAbGen
Class Antineoplastics; Immunotherapies; Immunotoxins; Monoclonal antibodies; Recombinant fusion proteins
Mechanism of Action Cell death stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Research Acute myeloid leukaemia

Most Recent Events

22 Feb 2023 Ordaos and FatiAbGen collaborate to develop monoclonal antibodies for treatment of Cancer
26 Aug 2022 FabG1 2139 is available for licensing as of 26 Aug 2022. http://www.fatiabgen.com/sub_fatiabgen.php
26 Aug 2022 Early research in Acute myeloid leukaemia in South Korea (Parenteral), as of August 2022 (FatiAbGen pipeline, August 2022)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com